Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters

Cardiovascular Drugs and Therapy

Volumn 13, Issue 6, 1999, Pages 525-530

  Paquette, France ^a   Jasmin, Gaëtan ^a   Dumont, Louis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cardiomyopathy; Cardioprotection; Hamster; Mibefradil; Verapamil

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; MIBEFRADIL; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAMSTER; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE NECROSIS; HEART PROTECTION; MALE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; TONGUE;

ANIMALS; BIOLOGICAL MARKERS; CALCINOSIS; CALCIUM CHANNEL BLOCKERS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CRICETINAE; FEMALE; HEART; MALE; MIBEFRADIL; MUSCLE, SKELETAL; MYOCARDIUM; NECROSIS; TIME FACTORS; TONGUE; VERAPAMIL;

EID: 0033400655     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007879704878     Document Type: Article

References (46)

1. 1. Clozel JP, Osterrieder W, Kleinbloesen CH, et al. Ro 40-5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drugs Rev 1991;9:4-17.
2. 2- channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989;13:754-759.
3. 3. Orito K, Satoh K, Taira N. Cardiovascular profile of Ro 40-5967, a new non-dihydropyridine calcium antagonist delineated in isolated blood-perfused dog hearts. J Cardiovasc Pharmacol 1993;22:293-299.
4. 4. Karila-Cohen D, Dubois-Randé JL, Giudicelli JF, Berdeaux A. Effects of mibefradil on large and small coronary arteries in conscious dogs: Role of the vascular endothelium. J Cardiovasc Pharmacol 1996;28:271-277.
5. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4;731-736.
6. 6. Véniant M, Clozel JP, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17;277-280.
7. 7. Roux S, Bühler M, Clozel JP. Mechanism of the antiischemic effect of mibefradil, a selective T calcium channel blocker in dogs: Comparison with amlodipine. J Cardiovasc Pharmacol 1996;27:132-139.
8. 8. Clozel JP, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721.
9. 9. Li J-S, Schiffrin EL. Effect of calcium blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;28;68-74.
10. 10. Vacher E, Richer C, Fornes P, Clozel JP, Giudicelli JF. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;27;686-694.
11. 11. Schmitt R, Clozel JP, Iberg I, Bühler FR. Prevention of neointima formation by mibefradil after vascular injury in rats: Comparison with Ace inhibition. Cardiovasc Drug Ther 1996;10;101-105.
12. 2- channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994;75:149-155.
13. 13. Factor SM, Minase T, Cho S, Dominitz R, Sonnenblick EH. Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis. Circulation 1982;66:342-354.
14. 14. Jasmin G, Proschek L. Calcium and myocardial cell injury. An appraisal in the cardiomyopathic hamster. Can J Physiol Pharmacol 1984;62:891-898.
15. 15. Jasmin G, Proschek L. Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. I. Progression of heart and skeletal muscle lesions in the UM-X7.1 line. Muscle and Nerve 1982;5:20-25.
16. 16. Mallory FB. Von Kossa's method for calcium. In: Pathological Techniques. New York: Hafner, 1961:114-125.
17. 17. Jasmin G, Eu HY. Cardiomyopathy of hamster dystrophy. Ann NY Acad Sci 1979;317:46-58.
18. 18. Bajusz E. Hereditary cardiomyopathy: A new disease model. Am Heart J 1969;77:686-696.
19. 19. Hamburger F. Myopathy of hamster dystrophy: History and morphological aspects. Ann NY Acad Sci 1979;317:2-17.
20. 20. Roberds SL, Ervasti JM, Anderson RD, Ohlendieck K, Kahl SD, Zoloto D. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem 1993;268:11496-11499.
21. 2+ stress. Circ Res 1991;69:123-133.
22. 22. Sole MJ, Lo C-M, Laird CW, Sonnenblick EH, Wurtman RJ. Norepinephrine turnover in the heart and spleen of the cardiomyopathic Syrian hamster. Circ Res 1975;37;855-862.
23. 23. Kundel B, Hofmann U, Mutschler M. Comparison of verapamil and bepridil in the therapy of familiar cardiomyopathy of the Syrian hamster. Z. Kardiol 1987;76(Suppl 3):159-613.
24. 24. Bhattacharya YH, Palmieri EA, Bertorini UE, Nuting DF. The effects of diltiazem on dystrophic hamsters. Muscle and Nerve 1982;5:73-78.
25. 25. Jasmin G, Proschek L. Pathogenesis of the hamster hereditary cardiomyopathy: a pharmacologic appraisal. In: Kawai C, Abelmann WH (eds). Pathogenesis of Myocarditis and Cardiomyopathy. Tokyo: University of Tokyo Press, 1987:79-89.
26. 26. Factor SM, Cho S, Scheuer J, Sonnenblick EH, Malhotra A. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J Am Coll Cardiol 1988;12:1599-1604.
27. 27. Jasmin G, Proschek L. Comparative effects of calcium antagonists and of inotropic agents on the development of hereditary cardiomyopathy in the hamster. In: Bender F, Meesmann W (eds). Treatment with Gallopamil. Darmstadt: Steinkoff Verlag, 1989:13-23.
28. 2+ channels. J Pharmacol Exp Ther 1994;271: 1483-1488.
29. 2+ channels by Ro 40-5967. Circ Res 1994;75:144-148.
30. 30. Figulla HR, Vetterlein F, Glaubitz M, Kreuzer H. Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. Circulation 1987;76:208-216.
31. 31. Conway RS, Natelson BH, Chen WH, Ting W. Enhanced coronary vasoconstriction in the Syrian myopathie hamster supports the microvascular spasm hypothesis. Cardiovasc Res 1994;28:320-324.
32. 32. Küng CF, Tschudi MR, Noll G, Clozel JP, Lüscher TF. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995;26:312-318.
33. ++ in dog coronary arterial vascular muscle cells by Ro 40-5967. J Cardiovasc Pharmacol 1994;24:1-7.
34. 34. Billman GE, Hamlin RL. The effects of mibefradil, a novel calcium channel antagonist, on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 1996;277:1517-1526.
35. 35. Hano O, Mitsuoka T, Matsumoto Y, et al. Arrhythmogenic properties of the ventricular myocardium in the cardiomyopathic Syrian hamster, BIO 14.6 strain. Cardiovasc Res 1991;25:49-57.
36. 36. Capasso JM, Sonnenblick EH, Anversa P. Chronic calcium channel blockade prevents the progression of myocardial contractile and electrical dysfunction in the cardiomyopathic Syrian hamster. Circ Res 1990;67:1381-1393.
37. 3H-mibefradil in vascular smooth muscle and heart membranes. Drug Res 1996;46:953-955.
38. 38. Abernethy DR. Pharmacologic and pharmacokinetic profile of mibefradil, a T-and L-type calcium channel antagonist. Am J Cardiol 1997;80:4C-11C.
39. 39. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokin 1992;22:416-433.
40. 40. Proschek L, Jasmin G. Hereditary polymyopathy and cardiomyopathy in the Syrian hamster. II. Development of heart necrotic changes in relation to defective mitochondrial function. Muscle and Nerve 1982;5:26-32.
41. 41. Saap JL, Howlett SE. Density of ryanodine receptors is increased in sarcoplasmic reticulum from prehypertrophic cardiomyopathic hamster heart. J Mol Cell Cardiol 1994;26: 325-334.
42. 2+ channels during development of heart failure in cardiomyopathic hamsters. Am J Physiol 1998;274: H1-H7.
43. 43. Zerning G. Photoaffinity labeling of the partially purified mitochondrial phenylalkylamine calcium antagonist receptor. Mol Pharmacol 1992;42:1010-1013.
44. 44. Valdivia HH, Valdivia C, Ma J, Coronado R. Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum. Biophys J 1990;58:471-481.
45. 45. Finkel MS, Shen L, Oddis CV, Romeo R. Verapamil regulation of the defective SR release channel in the cardiomyopathic Syrian hamster. Life Sci 1993;52:1109-1119.
46. 46. Hefti F, Clozel J-P, Osterrieder W. Antihypertensive properties of the novel calcium antagonist (1S,2S-2-[2-[[3-(2-benzimidazolly) propyl] methylamino] ethyl] -6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in the rat models. Comparison with verapamil. Drug Res 1990;40:417-421.